And AbbVie and Genmab scoop their ASH presentation with new data.
ApexOnco Front Page
Recent articles
The company adds royalty aggregation to its R&D business.
But Enhertu is coming.
A new first-line maintenance phase 3 joins a relapsed pivotal phase 2 study.
The restructured biotech’s new lead project enters phase 1.
But neladalkib results worsen, and come with a red flag about liver enzyme elevations.
The private biotech adds another asset to J&J’s prostate cancer pipeline.
The company will imminently start its third pivotal trial of PF-08634404.
